Abbvie Inc (ABBV)

[fuzzy]

AbbVie Inc. ABBV, +3.98% shares rose nearly 3% in pre-market trade after the company reported fourth-quarter profit and revenue beats and released upbeat 2018 guidance. Earnings for the latest quarter declined to $52 million, or 3 cents per share, from $1.39 billion, or 85 cents per share in the year-earlier period. Adjusted earnings-per-share were $1.48, compared with the FactSet consensus of $1.45. Revenue rose to $7.74 billion from $6.80 billion, compared with the FactSet consensus of $7.51 billion. Sales of Humira, Imbruvica, Lupron, Creon, Synagis, Kaletra, Sevoflurane and Duodopa came in above FactSet expectations, while sales of Synthroid and AndroGel missed expectations. AbbVie expects 2018 EPS of $6.45 to $6.55, compared with the FactSet consensus of $5.83, and raised adjusted EPS from between $6.37 and $6.57 to between $7.33 and $7.43, compared with the FactSet consensus of $5.56. The company said its 2017 results reflect provisional amounts related to U.S. corporate tax reform, but that estimates might be adjusted this year. AbbVie also touted plans to increase U.S. investments, including a proposal to invest about $2.5 billion in U.S. capital projects, possible expansion of its U.S. facilities, a one-time charitable donation of about $350 million to U.S. non-profits in 2018, added pension funding of about $750 million and greater compensation for non-executive employees.